Piramal Pharma — 360° view

Piramal Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹2,617 crore and net profit of ₹5.03 crore for the September 2026 quarter.

Piramal Pharma (NSE: PPLPHARMA) closed at ₹239.30 on 20 Nov 2026, up 26.2% over the past year. Its market capitalisation is ₹31,859 crore.

Share price
₹239.30 (20 Nov 2026)
Market cap
₹31,859 Cr (20 Nov 2026)
Revenue
₹2,617 Cr (September 2026 quarter)
Net profit
₹5 Cr (September 2026 quarter)
ROCE
2.52% (FY26)
ROE
-3.83% (FY26)
Book value
₹61.2 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹253.90 / ₹132.30 (20 Nov 2026)
1-year return
26.2% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: PPLPHARMA

Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion and Diagnostic Services was sold to Super Religare Laboratories (SRL)

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.